Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans 
Meta Says States Seek $1.4 Trillion in Penalties Over Teen Social Media Addiction Lawsuit 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
TetherMax Rebranding Highlights Official Exchange Partnerships and Transparent Operations 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Shell Raises Q2 Upstream Outlook, Flags Qatar Gas Hit as Shares Rise 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Barclays Downgrades Siemens Energy as Valuation Seen Near Peak 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
SpaceX Stock Draws Bullish Wall Street Coverage Ahead of Nasdaq-100 Inclusion 
CAMBRIDGE, Mass., May 08, 2018 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018, at 8 a.m. PT (11:00 a.m. ET) in Las Vegas, Nevada.
A live webcast of the presentation will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts
Media:
Cristi Barnett
(617) 401-0113
[email protected]
Investors:
Mark Mullikin
(617) 401-9083
[email protected]
